Incidence of metastatic breast cancer in an Australian population‐based cohort of women with non‐metastatic breast cancer at diagnosis

Lord, Sarah J.; Marinovich, M. Luke; Patterson, Jillian A.; Wilcken, Nicholas; Kiely, Belinda E; Gebski, Val; Crossing, Sally; Roder, David; Gattellari, Melina; Houssami, Nehmat

doi:10.5694/mja12.10026

Cited by 36 publications

(59 citation statements)

References 19 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Women's age (<50, 50-69, ≥70 years), node status (positive 'localised tumours', negative 'regionalised tumours'), morphology (invasive ductal, lobular, other), tumour size (>2 cm, ≤2 cm or unknown), area of residence (major city, other) and social disadvantage at diagnosis (least, middle, most) were obtained from the NSW Cancer Registry. Country of birth was reported by participants in the 45 and Up Study baseline survey (Australia or New Zealand, other).…”

Section: Demographic Clinical and Initial Treatment Characteristicsmentioning

confidence: 99%

“…9 However, these data are not available to researchers 12 and exclude women treated outside the hospital system (i.e. those receiving pharmacotherapy or radiotherapy only, administered on an outpatient basis in NSW).…”

Section: Introductionmentioning

confidence: 99%

“…Their study currently provides the only Australian population-based data for breast cancer recurrence and is one of the few international studies to estimate recurrence outside of clinical trials. 9 However, it is likely to underestimate the true incidence of breast cancer recurrence because local and regionalised recurrences were not captured, and women not receiving hospital treatment were excluded. 9 Australia has several linkable, whole-population administrative health datasets available to researchers that can potentially be used to estimate breast cancer recurrence rates, and which contain information about tumour characteristics and initial therapy that is not routinely collected by registries.…”

mentioning

confidence: 99%

“…9 However, it is likely to underestimate the true incidence of breast cancer recurrence because local and regionalised recurrences were not captured, and women not receiving hospital treatment were excluded. 9 Australia has several linkable, whole-population administrative health datasets available to researchers that can potentially be used to estimate breast cancer recurrence rates, and which contain information about tumour characteristics and initial therapy that is not routinely collected by registries. For example, Pharmaceutical Benefits Scheme (PBS) claims can be used to determine whether women have been dispensed trastuzumab for primary HER2-positive tumours, endocrine therapy for hormone receptor-positive tumours, or a therapy restricted for use in those with advanced breast cancer.…”

mentioning

confidence: 99%

“…To date, only one research group has obtained data on new episodes of treatment from the NSW Cancer Registry 9 , which were used to estimate rates of progression to distant metastasis (metastatic breast cancer). Lord and colleagues 9 estimated the 5-year cumulative incidence of metastatic cancer among 6644 women diagnosed with primary breast cancer in NSW in 2001−2002.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Breast cancer recurrence following active treatment: determining its incidence in the NSW population

Kemp-Casey¹,

Roughead

Saunders

et al. 2016

Public Health Research & Prac

View full text Add to dashboard Cite

Objectives: It is important for consumers, clinicians and health service planners to know the risk of recurrence of primary breast cancer after initial treatment. At present, none of Australia's state or territory cancer registries routinely report this information. We aimed to determine the incidence of recurrence in New South Wales (NSW) clinical practice for the period 18 months to 6 years after diagnosis of primary breast cancer. Study type:Retrospective cohort study using population-based linked health data. Methods:We identified 2416 women in the 45 and Up Study who were diagnosed with primary invasive breast cancer between 2003 and 2008 in NSW, and who had not had a recurrence 18 months after diagnosis. Unit-level hospital, pharmacy and outpatient medical claims were used to identify treatment for recurrence. Incidence of recurrence was calculated using individual person-time at risk (18 months to 6 years postdiagnosis), with follow-up censored for death or end of study period (median follow-up 3 years). Time to recurrence was calculated, and Cox proportional regression was used to identify women's baseline and active treatment characteristics that were predictive of recurrence up to 6 years postdiagnosis.Results: 217 women (9%) had a hospital, pharmacy or outpatient claim indicating breast cancer recurrence. Overall annual incidence of recurrence was 3.3%. Recurrence rates were significantly higher for women with nodepositive (4.8% vs 2.5% annually; hazard ratio [HR] = 1.7; 95% confidence interval [95% CI] 1.3, 2.3) or hormone receptor-negative tumours (3.8% vs 3.1% annually; HR = 1.3; 95% CI 1.0, 1.7). Women with tumours >2 cm at diagnosis were more likely to experience recurrence than women with smaller/unknown tumours (4.8% vs 2.7% annually; HR = 1.5; 95% CI 1.1, 2.0).

show abstract

Section: Demographic Clinical and Initial Treatment Characteristicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Breast cancer recurrence following active treatment: determining its incidence in the NSW population

Kemp-Casey¹,

Roughead

Saunders

et al. 2016

Public Health Research & Prac

View full text Add to dashboard Cite

show abstract

Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)

Saadatmand

Obdeijn

Rutgers

et al. 2015

Intl Journal of Cancer

View full text Add to dashboard Cite

Adding MRI to annual mammography screening improves early breast cancer detection in women with familial risk or BRCA1/2 mutation, but breast cancer specific metastasis free survival (MFS) remains unknown. We compared MFS of patients from the largest prospective MRI Screening Study (MRISC) with 1:1 matched controls. Controls, unscreened if<50 years, and screened with biennial mammography if 50 years, were matched on risk category (BRCA1, BRCA2, familial risk), year and age of diagnosis. Of 2,308 MRISC participants, breast cancer was detected in 93 (97 breast cancers), who received MRI <2 years before breast cancer diagnosis; 33 BRCA1 mutation carriers, 18 BRCA2 mutation carriers, and 42 with familial risk. MRISC patients had smaller (87% vs. 52%

show abstract

αvβ1 integrin is enriched in extracellular vesicles of metastatic breast cancer cells: A mechanism mediated by galectin‐3

Zhang

Dang

et al. 2022

J of Extracellular Vesicle

View full text Add to dashboard Cite

Breast cancer cells release a large quantity of biocargo-bearing extracellular vesicles (EVs), which mediate intercellular communication within the tumour microenvironment and promote metastasis. To identify EV-bound proteins related to metastasis, we used mass spectrometry to profile EVs from highly and poorly metastatic breast cancer lines of human and mouse origins. Comparative mass spectrometry indicated that integrins, including αv and β1 subunits, are preferentially enriched in EVs of highly metastatic origin over those of poorly metastatic origin. These results are consistent with our histopathological findings, which show that integrin αv is associated with disease progression in breast cancer patients. Integrin αv colocalizes with the multivesicular-body marker CD63 at a higher frequency in the tumour and is enriched in circulating EVs of breast cancer patients at late stages when compared with circulating EVs from early-stage patients. With a magnetic bead-based flow cytometry assay, we confirmed that integrins αv and β1 are enriched in the CD63 + subsets of EVs from both human and mouse highly metastatic cells. By analysing the level of integrin αv on circulating EVs, this assay could predict the metastatic potential of a xenografted mouse model. To explore the export mechanism of integrins into EVs, we performed immunoprecipitation mass spectrometry and identified members of the galectin family as potential shuttlers of integrin αvβ1 into EVs. In particular, knockdown of galectin-3, but not galectin-1, causes a reduction in the levels of cell surface integrins β1 and αv, and decreases the colocalization of these integrins with CD63. Importantly, knockdown of galectin-3 leads to a decrease of integrin αvβ1This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Incidence of metastatic breast cancer in an Australian population‐based cohort of women with non‐metastatic breast cancer at diagnosis

Cited by 36 publications

References 19 publications

Breast cancer recurrence following active treatment: determining its incidence in the NSW population

Breast cancer recurrence following active treatment: determining its incidence in the NSW population

Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)

αvβ1 integrin is enriched in extracellular vesicles of metastatic breast cancer cells: A mechanism mediated by galectin‐3

Contact Info

Product

Resources

About